GlaxoSmithKline Pharmaceuticals
- Advice
- Hold
Glaxosmithkline Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in GlaxoSmithKline Pharmaceuticals
Start SIPGlaxosmithkline Pharmaceuticals Investment Rating
-
Master Rating:
-
Glaxosmithkline Pharms. has an operating revenue of Rs. 3,287.52 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 24% is great, ROE of 63% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 118 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|
| Oper Rev Qtr Cr | 906 | 729 | 792 |
| Operating Expenses Qtr Cr | 649 | 582 | 619 |
| Operating Profit Qtr Cr | 257 | 148 | 173 |
| Depreciation Qtr Cr | 16 | 16 | 15 |
| Interest Qtr Cr | 0 | 1 | 0 |
| Tax Qtr Cr | 69 | 44 | 262 |
| Net Profit Qtr Cr | 194 | 119 | 1,218 |
Glaxosmithkline Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 1295.67
- 50 Day
- 1318.31
- 100 Day
- 1353.28
- 200 Day
- 1410.52
- 20 Day
- 1297.16
- 50 Day
- 1317.29
- 100 Day
- 1351.07
- 200 Day
- 1429.84
Glaxosmithkline Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1272.3 |
| Second Resistance | 1281.6 |
| Third Resistance | 1289.25 |
| RSI | 27.09 |
| MFI | 44.34 |
| MACD Single Line | -11.18 |
| MACD | -14.9 |
| Support | |
|---|---|
| First Resistance | 1255.35 |
| Second Resistance | 1247.7 |
| Third Resistance | 1238.41 |
Glaxosmithkline Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 173,151 | 16,253,684 | 93.87 |
| Week | 63,601 | 5,411,194 | 85.08 |
| 1 Month | 47,426 | 3,719,621 | 78.43 |
| 6 Month | 69,609 | 5,144,077 | 73.9 |
Glaxosmithkline Pharmaceuticals Result Highlights
GlaxoSmithKline Pharmaceuticals Synopsis
NSE-Medical-Diversified
Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3217.51 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2022. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.| Market Cap | 21,482 |
| Sales | 3,235 |
| Shares in Float | 4.24 |
| No of funds | 201 |
| Yield | 2.38 |
| Book Value | 7.99 |
| U/D Vol ratio | 0.9 |
| LTDebt / Equity | |
| Alpha | -0.08 |
| Beta | 0.24 |
GlaxoSmithKline Pharmaceuticals
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 75% | 75% | 75% | |
| Mutual Funds | 4.12% | 3.82% | 4.06% | |
| Insurance Companies | 6.1% | 6.62% | ||
| Foreign Portfolio Investors | 2.28% | 2.17% | 2.16% | |
| Financial Institutions/ Banks | 0.01% | 0.01% | 0.02% | |
| Individual Investors | 10.56% | 10.4% | 10.41% | |
| Others | 1.93% | 1.98% | 8.35% |
GlaxoSmithKline Pharmaceuticals Management
| Name | Designation |
|---|---|
| Ms. R S Karnad | Chairperson |
| Mr. Sridhar Venkatesh | Managing Director |
| Dr.(Ms.) S Maheshwari | Director |
| Mr. S Williams | Director |
| Mr. P V Bhide | Director |
| Mr. N Kaviratne | Director |
| Mr. A N Roy | Director |
| Mr. D Sundaram | Director |
| Mr. M Anand | Director |
| Mr. J Chandy | Director |
Glaxosmithkline Pharmaceuticals Forecast
Price Estimates
Glaxosmithkline Pharmaceuticals Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-02-07 | Quarterly Results | |
| 2022-11-11 | Quarterly Results | |
| 2022-07-25 | Quarterly Results | |
| 2022-05-16 | Audited Results & Dividend | |
| 2022-02-07 | Quarterly Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2022-07-08 | FINAL | Rs.30.00 per share(300%)Dividend |
| 2022-07-08 | SPECIAL | Rs.60.00 per share(600%)Special Dividend |
| 2021-07-20 | FINAL | Rs.30.00 per share(300%)Dividend |
GlaxoSmithKline Pharmaceuticals FAQs
What is Share Price of GlaxoSmithKline Pharmaceuticals ?
GlaxoSmithKline Pharmaceuticals share price is ₹1269 As on 30 January, 2023 | 10:41
What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹21507.8 Cr As on 30 January, 2023 | 10:41
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 12.8 As on 30 January, 2023 | 10:41
What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?
The PB ratio of GlaxoSmithKline Pharmaceuticals is 8.1 As on 30 January, 2023 | 10:41